Su-9516 is primarily utilized in biochemical research as a potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2). It is widely employed in studies aimed at understanding the role of CDK2 in cell cycle regulation, particularly in the G1 to S phase transition. Researchers use Su-9516 to investigate its effects on cancer cell proliferation, as CDK2 is often implicated in the uncontrolled growth of tumor cells. Additionally, it serves as a valuable tool in exploring potential therapeutic strategies for cancer treatment by targeting CDK2 activity. Its application extends to in vitro and in vivo experiments, helping to elucidate molecular pathways and validate CDK2 as a drug target.